Meetings archive 2009
From Mekong to Bali: the scale up of collaborative TB/HIV activities in Asia Pacific Region.
8-9 August, 2009 | Bali, Indonesia
Catalyzing the implementation of collaborative HIV/TB activities in the Asia and Pacific regions is a key priority. This region has more than half of the global burden of TB and 12% of the global burden of HIV. To this end the meeting "From Mekong to Bali: scale up of HIV/TB collaborative activities in Asia Pacific" was organized by the World Health Organization (WHO) in collaboration with the HIV/TB Working Group of the Stop TB Partnership. 127 people from 18 countries participated in the meeting with representation from all high TB and HIV burden countries. Participants shared experiences and best practices to inform plans to accelerate the implementation of nation-wide scale up of collaborative HIV/TB activities. The meeting followed on from the first regional HIV/TB meeting held in the Mekong sub region in Ho Chi Minh City, Viet Nam in October 2004. National TB and HIV program managers were joined by a broad range of AIDS and TB stakeholders active in the Asia and Pacific regions, members of the HIV/TB Working Group and representatives of bilateral and multilateral organizations, NGOS, and faith based organizations. The presentations and posters from the meeting are available below. The final meeting report is available here.
General
List of participants | Programme
ICAAP Plenary
Jintama Ngamvithayapong-Yanai, Asia-Pacific
Session 1
Dr Cheng, Shiming China
Dr Massimo, TB_HIV ICAAP MNG
Dr Nani Nair, SEA Regional overview and response to TB-HIV BaliF
Dr Sriprapa Nateniyom, Thailand
Session 2
Dr Anjana Das, Bali
Dr Anthony, Bali
Dr Fabio Mesquita, Bali
Session 3
Dr Christian Gunneberg
Dr Khun Kim Eam
Dr Marco Vitoria, Management of TB-HIV
Dr Sri Chandra, TB-HIV Program Experience - World Vision, Thailand
Session 4 - Group Work outputs
Group 1: Testing TB patentins and ART provision
Group 2: Intensified TB case finding & isonniazid prophylaxis
Group 3: Partnership contribution to TBHIV scale up
Group 4: Services for drug users TBHIV sale up
Group 5: Community involvement TBHIV Scale up
Group 6: Infection control TBHIV scale up
Session 5
Remarks by Nafis Sadik_UN Special Envoy for HIVAIDS in Asia
Struminger, PEPFAR, TB Bali
Swarup Sakar
Session 6
Massimo Ghidinelli NS
Puneet Deevan NS
TB/HIV at IAS 2009
Catalysing HIV/TB research: innovation, funding and networking
18-21 July, 2009
Making TB research a priority
The consequences of inattention to TB research are not just embarrassing, they are tragic and shameful. Generations of research advances and technologies have bypassed the field of TB research. All of the great breakthroughs that we have seen in molecular biology - there was nobody working on it in TB.
Nine million people develop active TB each year and yet we still don't have an effective vaccine. There have been no newly licensed drugs for TB in forty years [with the exception of rifabutin]. The therapeutic regimens, although they work, are cumbersome and prone to the development of drug resistance. The diagnostics are ridiculous, they are antiquated, non-standardised and imprecise.
- Dr Tony Fauci, Director of the US National Institute of Allergy and Infectious Diseases (NIAID) at a meeting held in Cape Town just prior to IAS 2009
The World Health Organization and the TB/HIV Working Group of the Stop TB Partnership in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), International AIDS Society, Treatment Action Group and the Desmond Tutu HIV Centre of University of Cape Town organized a highly visible meeting in conjunction with the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa on 18-19 July, 2009.
The meeting was attended by about 250 HIV researchers, activists and representatives from funding agencies. The meeting focused on critical TB/HIV issues in the areas of TB prevention, diagnosis and treatment, childhood TB and drug resistant TB. New and previously unreported data was shared, discussed and research priorities were defined. The research priority discussions during the meeting also informed the ongoing revision of the TB/HIV research priorities document by the World Health Organisation, which will soon be finalised. Presentations from the meeting are available at here. The outcome and key findings of the meeting were communicated to the IAS conference delegates through a satellite symposium on 21 July, 2009. Webcast of the satellite symposium is available at http://www.ias2009.org/pag/webcasts/?sessionid=2449
21 July, 2009
Preventing TB in People Living with HIV: research priorities and way forward by Peter Godfrey-Faussett, UK
TB in HIV-infected Children: addressing the research neglect by Soumya Swaminathan, India
Drug resistance TB in People Living with HIV: research questions and priorities by Haileyesus Getahun, Switzerland
Clinical challenges of diagnosing and treating TB in People Living with HIV: what next for research? By Prudence Ive, South Africa
19 July, 2009 - Key note presentation
Challenges on TB-HIV Research by Françoise Barré-Sinoussi, France
Watch Dr. Barré-Sinoussi's plenary presentation
Research activism from HIV to TB by Mark Harrington, USA
Session III: Childhood TB
TB diagnosis in Children: experience with HIV-infected children by Anneke Hesseling, South Africa
ARV TB drug experience in children: when and what to start? By Philippa Musoke, Uganda
Mother to child transmission of TB: what do we know? By Amita Gupta, India
Developing safer TB vaccines for children with HIV by Jerald Sadoff, USA
Session IV: Drug resistance TB and HIV
MDR, XDR TB and HIV: global data, approaches and operational research issues by Paul Nunn, Switzerland
MDR and XDR TB in people living with HIV: what do we know and what we still need to know by Neel Gandhi, USA
Drug resistance TB and new diagnostics for people living with HIV: emerging data from FIND by Giorgio Roscigno, Switzerland
Molecular epidemiology: role for transmission of MDR/XDR by Paul van Helden, South Africa
July 18, 2009 - Key note presentations
HIV/TB overview and rationale of meeting by Diane Havlir, USA
Research on TB and HIV/AIDS: Progress and Challenges by Anthony Fauci, USA
Watch Dr. Fauci's plenary presentation
Session I: Diagnosis and Treatment
Strategies for co-treatment: first and second line ART and TB treatment by Gary Maartens, South Africa
Role of TB in early mortality of people living with HIV by Mina Hosseinipour, Malawi
Sub-clinical TB among people living with HIV: what does the evidence say? By Haileyesus Getahun, Switzerland
The latest developments in diagnosis and management of TB IRIS: what are the gaps? By Graeme Meintjes, South Africa
Session II: TB Prevention
Isoniazid preventive therapy: outcome of massive scale-up among miners in South Africa by Gavin Churchyard, South Africa
TB infection control among people living with HIV: what do we know? By Rod Escombe, UK
Impact of ART on TB Prevention by Robin Wood, South Africa
TB diagnosis in the community: approaches and outcomes by Helen Ayles, Zambia
In 2009, HIV & AIDS Treatment in Practice (HATIP) echoed these sentiments, stating that TB research has long been neglected and under funded. [100KB]. But the participation of Dr Fauci, Nobel Prize winner Dr Françoise Barré-Sinoussi of the Institut Pasteur, and many others from the HIV research establishment at a recent meeting was a clear sign that some of the world's pre-eminent research institutions are finally moving to make TB research a priority. (Read the full article Catalysing HIV/TB Research: a meeting report by Theo Smart, HATIP).
TB/HIV at CROI 2009
8-11 February 2009 | Montreal, Canada
The Stop TB Department of WHO in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) organized a meeting affiliated with the 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009) in Montreal, Canada. This is the third in a series of meetings organized since 2007.
The meetings have successfully raised the profile of HIV/TB among HIV researchers in particular by sharing data from ongoing studies, identifying research gaps and stimulating further HIV/TB research. The main objective of the meeting at CROI 2009 was to promote high level scientific interchange of ideas and research priorities to have a better understanding of the magnitude and burden of TB (including drug resistant strains) especially in HIV prevalent settings.
Presentations
PK and Drug Interactions in a Changing World: New Drugs for TB and New Regimens for TB-HIV Co-infection by Charles Flexner, MD, Johns Hopkins University
Treatment of Extensively Drug Resistant Tuberculosis Among Patients with HIV Infection in South Africa by Max O'Donnell, Nesri Padayatchi, Iqubal Master, Garth Osburn, Robert Horsburgh
Sensitivity, specificity and predictive values of symptoms to detect tuberculosis in the ZAMSTAR community based prevalence studies by Peter Godfrey-Faussett and Helen Ayles, London School of Hygiene and Tropical Medicine, UK
